#132: "Real-world" analysis: New anticoagulants better than warfarin in AF; PTCA pioneer passes away: Dr Geoffrey Hartzler; Florida stem-cell cardiologist has license suspended; Dabigatran cost-effective vs warfarin; theheart.org's statin safety survey
"Real-world" analysis: New anticoagulants better than warfarin in AF; PTCA pioneer passes away: Dr Geoffrey Hartzler; Florida stem-cell cardiologist has license suspended; Dabigatran cost-effective vs warfarin; theheart.org's statin safety survey (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - March 16, 2012 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
#130: FDA adds warnings to statin label; nine brain-cancer cases in interventionalists; why cardiac death risk is highest in early morning: discovery; Predictors of ICH include warfarin treatment; no mortality or MI benefit in stable CAD patients treated
FDA adds warnings to statin label; nine brain-cancer cases in interventionalists; why cardiac death risk is highest in early morning: discovery; Predictors of ICH include warfarin treatment; no mortality or MI benefit in stable CAD patients treated (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - March 2, 2012 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
#124: Resveratrol researchers on Das fraud scandal; BRIDGE study published; US bleeding ADRs: dabigatran vs warfarin; statins: four times more costly in US than UK; dronedarone gets another chance in combo trial
Resveratrol researchers on Das fraud scandal; BRIDGE study published; US bleeding ADRs: dabigatran vs warfarin; statins: four times more costly in US than UK; dronedarone gets another chance in combo trial (Source: Radio TheHeart.org)
Source: Radio TheHeart.org - January 20, 2012 Category: Cardiology Authors: theheart.org Tags: This week in cardiology from heartwire Source Type: podcasts
#35: Oral antithrombotic agents: An update for the clinical practitioner with Dr Jonathan Halperin
After decades of reliance on warfarin, there are finally new options for oral anticoagulation, with exciting results from the RE-LY, ROCKET, and AVERROES trials paving the way for dabigatran, rivaroxaban, and apixaban. (Source: The Bob Harrington Show)
Source: The Bob Harrington Show - April 14, 2011 Category: Cardiology Authors: theheart.org Tags: The Bob Harrington Show Source Type: podcasts
Episode #28: AVERROES: Apixaban as a future alternative to warfarin with Dr Stuart Connolly
The findings of the AVERROES trial foretell a future with appropriate treatment for patients with atrial fibrillation who are not candidates for anticoagulation with oral vitamin-K antagonists. (Source: The Bob Harrington Show)
Source: The Bob Harrington Show - October 7, 2010 Category: Cardiology Authors: theheart.org Tags: The Bob Harrington Show Source Type: podcasts
